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Center-driven and Clinically Driven Variation
in US Liver Transplant Maintenance
Immunosuppression Therapy: A National
Practice Patterns Analysis
Mustafa Nazzal, MD,1 Krista L. Lentine, MD, PhD,1 Abhijit S. Naik, MD, MPH,2 Rosemary Ouseph, PhD,1
Mark A. Schnitzler, PhD,1 Zidong Zhang, MPH,1 Henry Randall, MD,1 Vikas R. Dharnidharka, MD, MPH,3
Dorry L. Segev, MD, PhD,4 Bertram L. Kasiske, MD,5 Gregory P. Hess, MD, MSc,6 Tarek Alhamad, MD, MSc,7
Mara McAdams-Demarco, PhD,4 and David A. Axelrod, MD, MBA8
Background. Variation in the use of immunosuppression regimens after liver transplant has not been well described.
Methods. Immunosuppression regimens used after liver transplant were identified in a novel database integrating national
transplant registry and pharmacy fill records for 24 238 recipients (2006-2014). Bilevel hierarchical models were developed
to quantify the effects of transplant program, recipient, and donor characteristics on regimen choice. Results. In the first
6 months after transplant, triple immunosuppression (tacrolimus, antimetabolite, corticosteroids) was the most common regimen
(42.9%). By months 7 to 12, immunosuppression regimens were more commonly antimetabolite sparing (33.7%) or steroid spar-
ing (26.9%), followed by triple (14.4%), mammalian target of rapamycin inhibitor (mTORi)-based (12.1%), or cyclosporine-based
(9.2%). Based on intraclass correlation analysis, clinical characteristics explained less than 10% of the variation in immunosup-
pression choice, whereas program preference/practice explained 23% of steroid sparing, 26% of antimetabolite sparing, 28%
of mTORi, and 21% of cyclosporine-based regimen use. Although case factors were not dominant practice drivers, triple immu-
nosuppression in months 7 to 12 was more common among retransplant recipients and those with prior acute rejection. Hepa-
tocellular carcinoma as cause of liver failure (adjusted odds ratio [aOR], 2.15; P<0.001), cancer within 6 months (aOR, 6.07;
P<0.001), and 6-month estimated glomerular filtration rate less than 30mL/min per 1.3m2 (aOR, 1.98; P<0.001) were associated
with mTORi use compared with triple immunosuppression in months 7 to 12, whereas acute rejection predicted lower use (aOR,
0.72; P=0.003).Conclusions. Liver transplant immunosuppression is dominantly driven by program preference, but case fac-
tors also affect regimen choice. This variation frames a natural experiment for future evaluations of comparative efficacy.
(Transplantation Direct 2018;4: e364; doi: 10.1097/TXD.0000000000000800. Published online 13 June, 2018.)
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L iver transplant recipients have traditionally requiredlower levels of immunosuppression (ISx) than other solid
organ transplant recipients. However, inadequate ISx coverage
can result in acute rejection (AR) and graft loss, whereas
overuse contributes to chronic renal insufficiency, malig-
nancy, and infection.1 A recent Cochrane review of induction
and maintenance ISx in liver transplantation concluded that
published data were insufficient to identify an optimal ISx,
and called for novel strategies to assess variation in ISx-
related outcomes.2 The development of novel “big data”
linking administrative and clinical data sets offers the potential
to assess outcome variation by ISx regimen while controlling
for marked differences in patient and donor characteristics
which characterize contemporary liver transplant practice.
Calcineurin inhibitor (CNI)-based regimens including
tacrolimus (Tac) or cyclosporine (CsA) remain the founda-
tion of postliver transplant maintenance ISx. Calcineurin
inhibitor–based ISx results in low rates of AR and prolonged
graft survival, and Tac is associated with better outcomes
than CsA in head-to-head comparison.3 However, in sub-
populations, alternative regimens may be superior, because
Tachasbeenassociatedwith an increase indenovomalignancies,
a 40% increased risk of posttransplant diabetes, and more ag-
gressive recurrence of autoimmune disease.4 In addition, CNIs
contribute to the development of chronic kidney disease (glomer-
ular filtration rate [GFR] <30 mL/min per 1.73 m2) in nearly
20%of liver transplant recipients at 5 years.5 Strategies to de-
crease the nephrotoxicity associated with CNIs include the
use of induction therapy to delay CNI introduction and con-
version to mammalian target of rapamycin inhibitor (mTORi)
maintenance to allow lower CNI therapeutic levels or avoid
CNIs altogether.6,7 Unfortunately, mTORis have been associated
with hepatic artery thrombosis and increased AR rates, which
could mitigate the advantages of mTORi on kidney function.8,9
Patients with hepatocellular cancer (HCC) represent a
growing proportion of liver transplant recipients who may
benefit from a tailored ISx strategy. Hepatocellular cancer
recurrence is believed to be influenced by degree of ISx, is
difficult to treat, and leads to high mortality.10 The mTORi-
based regimens may have some antineoplastic benefits for
patients withHCC.11 Although the use of sirolimus (SRL) is par-
ticularly challenging early posttransplant due to risk of vascular
complications and poor wound healing, selected trials have sug-
gested benefit if therapy is delayed for at least 30 days.8,9
The evaluation of customized ISx strategies in liver trans-
plantation has thus far been limited to trends in ISx use after
liver transplant have been reported using national registry
data at time of discharge.2,12 To characterize contemporary
practices in liver transplant ISx, we examined a novel data-
base integrating national registry and pharmacy fill records
for a national, contemporary sample of US liver transplant
recipients using a multilevel analytic framework in the early
(0-6 months) and later (7-12 months) posttransplant periods
as distinguish between clinically driven differences in ISx reg-
imen and those based simply on established practice.
MATERIALS AND METHODS
Data Sources
We conducted a retrospective cohort study using linked
healthcare databases in the US to ascertain patient character-
istics, pharmacy fill records, and outcome events for liver
transplant recipients. This study used transplant data from
the Scientific Registry of Transplant Recipients (SRTR). The
SRTR system includes data on all donors, waitlisted candi-
dates, and transplant recipients in the US, submitted by the
members of the Organ Procurement and Transplantation
Network (OPTN). The Health Resources and Services Ad-
ministration, US Department of Health andHuman Services,
provides oversight of the activities of the OPTN and SRTR
contractors. Baseline demographic information ascertained
for liver transplant recipients from OPTN included age, sex,
and race as reported by the transplant centers.
Pharmacy fill data were assembled by linking SRTR re-
cords for liver transplant recipients with billing claims from
Symphony Health (SH), a large US pharmaceutical claims
data warehouse that collects prescription drug fill records
including self-paid fills and those reimbursed by private
and public payers.13 Symphony Health comprises National
Council for Prescription Drug Program format prescription
claims aggregated from multiple sources including claims
warehouses, retail pharmacies, and prescription benefit man-
agers for approximately 60% of US retail pharmacy transac-
tions. Individual claim records include the pharmacy fill date
with the national drug code identifying agent and dosage. Af-
ter institutional review board and Health Resources and Ser-
vices Administration approvals, SH records were linked with
SRTR records for liver transplant recipients.We applied a de-
terministic deidentification strategy wherein patient identi-
fiers (last name, first name, date of birth, sex, and ZIP code
of residence) were transformed before delivery to the Saint
Louis University researchers with Health Information Por-
tability and Accountability Act and Health Information
Technology for Economic and Clinical Health (HITECH)-
certified encryption technology from SH. The patient
deidentification software employs multiple encryption algo-
rithms in succession to guarantee that the resulting “token”
containing encrypted patient identifiers can never be
decrypted. However, the algorithm yields the same results
for a given set of data elements, such that linkages by
unique anonymous tokens are possible.
Sample and Clinical Characteristics
We identified adult liver transplant recipients (age, ≥18
years) with SRTR records of liver transplant in 2006 and
2014 and available pharmaceutical fill records over
12 months posttransplant. Recipient clinical and demo-
graphic characteristics, characteristics of the donated organ,
and other transplant factors including ischemic time and
sharing, were defined by the OPTN Transplant Candidate
and Recipient Registration forms (Table 1).
Immunosuppression
Using pharmacy fill records, ISx regimens were classified
into 6 mutually exclusive groups as per previous methods:
group 1 (reference), standard triple therapy, defined as Tacwith
mycophenolic acid (MPA) (mycophenolate mofetil, myco-
phenolate sodium), or azathioprine (AZA), and prednisone
(Pred), “Tac+MPA/AZA+Pred”; group 2, corticosteroid-
sparing, “Tac+MPA/AZA”; group 3, MPA/AZA sparing,
“Tac alone, Tac+Pred”; group 4, mTORi-based, defined by
any fill for SRL as the mTORi available in the study period,
with or without other agents including CNI, “mTORi-
based”; group 5, CsA-based, defined by CsA without SRL,
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TABLE 1.
Recipient, donor, and transplant characteristics according to liver transplant maintenance ISx regimen, months 0 to
6 posttransplant
Tac + MPA/AZA+Pred Tac + MPA/AZA Tac alone, Tac + Pred mTORi-based CsA-based Other
Sample size 10 396 3736 4385 2447 2124 1150
Induction regimen a a a a a
No induction 81.7 59.9 67.3 66.2 68.2 74.0
Thymoglobulin 3.0 19.6 14.6 12.2 9.2 8.5
IL-2 receptor antibody 14.6 17.5 12.7 19.5 20.4 16.1
Alemtuzumab 0.1 0.5 2.5 0.5 0.4 0.4
Other induction 0.6 2.5 2.9 1.6 1.7 1.0
Recipient characteristics
Age, y a b a a b
18-30 5.0 3.2 4.6 2.3 3.1 5.2
31-45 12.7 11.5 11.5 8.2 9.2 11.7
46-60 54.1 61.2 57.3 56.0 59.6 58.4
>60 28.2 24.1 26.6 33.5 28.1 24.8
Male 59.2 59.1 59.9 59.2 58.7 59.0
Race c a c c
White 73.8 73.6 73.9 76.5 75.9 71.3
Black 8.2 10.0 8.9 9.4 7.1 11.5
Hispanic 12.1 11.7 12.1 10.0 13.0 13.0
Other 5.9 4.7 5.1 4.2 4.1 4.3
BMI, kg/m2 b
<18.5 1.8 2.1 2.2 1.4 2.0 2.4
18.5-24.9 29.4 27.4 28.2 27.2 28.3 27.0
25-30 33.1 34.0 35.2 35.5 35.2 34.8
>30 34.2 34.8 32.5 34.2 33.3 34.0
Unknown 1.6 1.9 1.9 1.8 1.2 1.8
Cause of liver failure a a a a a
Hepatocellular carcinoma 21.2 25.4 23.9 30.5 17.6 22.1
Hepatitis C 23.2 30.6 27.6 24.6 36.0 28.5
Hepatitis B 1.8 1.9 1.9 1.7 1.9 1.7
Metabolic 2.5 1.9 2.4 2.3 2.3 2.2
Alcoholic 13.4 12.5 12.6 11.7 13.8 9.9
NASH 7.9 7.3 6.3 8.5 7.4 5.7
Other/Unknown 30.0 20.5 25.3 20.8 21.1 29.9
Comorbidities
Diabetes 0.2 0.3 0.3 0.3 0.2 0.4
Coronary artery disease/angina 1.8 2.6b 2.7c 2.1 2.5b 2.0
COPD 1.7 2.3b 1.5 1.4 2.4b 1.7
Hypertension 20.3 20.9 18.9 24.1a 20.5 20.7
Cerebral vascular diseases 0.8 0.5 0.5b 0.7 0.6 0.5
Peripheral vascular diseases 0.9 1.1 0.8 0.7 0.8 0.7
Malignancy history 19.2 20.3 23.0a 23.2a 18.8 18.0
Laboratory MELD score b b c
10-14 41.5 44.1 44.6 44.5 36.5 43.4
15-19 22.5 23.6 22.3 21.3 24.5 21.4
20-24 12.9 12.4 12.8 12.4 13.5 14.0
25-29 8.1 7.1 7.6 7.7 9.8 8.4
30-34 6.4 5.3 5.3 6.3 7.5 5.8
35-39 4.7 3.9 4.3 3.7 4.2 3.6
≥40 3.9 3.6 3.2 4.1 4.0 3.5
Primary insurance b c
Private 63.2 63.1 60.5 62.7 59.0 61.7
Public 36.1 36.4 38.5 36.4 40.2 37.4
Self/other 0.7 0.5 1.0 0.9 0.9 0.9
Continued next page
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“CsA-based”; group 6, “other regimens” including CsA
withdrawal, or other trial medications.13 Patients in groups
1 to 3 did not receive SRL or CsA.
Analyses
Observed Variation in Regimen Use Across Centers
To visually assess unadjusted variation in maintenance ISx
use at the center level across the United States, the observed
proportion of patients receiving each induction regimen was
computed for each center and displayed as stacked bar plots.
Combined Center and Case-level Modeling
Bilevel hierarchical models were constructed to adjust for
clustering effects. Level 1 comprised patient/donor and trans-
plant (clinical) factors, and level 2 represented the center,
wherein use of each alternative regimen was compared indi-
vidually to the reference regimen (pairwise). Empirical Bayes
estimates (EBE) provided the adjusted proportion (with 95%
confidence intervals [CI]) of use of a regimen of interest com-
pared with the reference regimen, incorporating case-mix ad-
justment from the hierarchical model. A 95% CI for a given
center's EBE of use of a regimen of interest that did not in-
clude the median national rate of use indicated a prescribing
pattern statistically significantly different from the expected
rate of use for that regimen.
Heterogeneity in ISx prescribing across centers was quanti-
fied using intraclass correlation (ICC) and median odds ratios
(MOR). The ICC is defined as the ratio of cluster variance
(center impact) to the total observed variance in ISx use,
with contributions in our study framework defined as
center-related, clinically related, and other unmeasured ef-
fects. In this context, the ICC quantifies the proportion of to-
tal variance in ISx use that is accounted for by center. The
MOR provides the median of the odds that patients with
identical characteristics will receive the ISx regimen of inter-
est when 2 centers are drawn at random (performed for all
possible pairs of centers). For example, a MOR of 2.0 means
that if centers are selected at random across all centers, a pa-
tientwith a given set of characteristics is, on an average, twice
as likely to receive the ISx regimen of interest at one of the
randomly selected centers as at the other.14 The adjusted
odd ratio (95% LCL aOR95% UCL) of receiving a maintenance
regimen other than the triple-therapy reference was deter-
mined for patient and donor factors, after accounting for
the effect of center using the hierarchical model.
Data were analyzed using Stata 13, College Station, TX.
Hierarchical logistic regression modeling was in Stata using
the “xtmelogit” commandwith center as a random intercept.
The ICC and theMORwere calculated using “xtmrho” (third-
party suite) command.
Contributions of Case-level Factors to Variation in
ISx Use
To quantify the degree of variance in ISx regimen use ex-
plained by recipient and donor characteristics, we performed
multivariate logistic regression modeling with maintenance
regimen as the dependent variable and case factors as the pre-
dictors. Pairwise models were constructed to assess the rela-
tive likelihood of using each specific regimen (as outlined
above) compared with triple ISx.
TABLE 1. (Continued)
Tac + MPA/AZA+Pred Tac + MPA/AZA Tac alone, Tac + Pred mTORi-based CsA-based Other
Previous transplant 8.2 7.2b 9.5 6.8b 11.2a 11.8a
eGFR at discharge, ml/min per 1.73 m2 a a c b
≥ 90 33.1 34.3 38.9 25.8 29.6 31.7
60-89 23.5 23.3 24.8 22.8 25.6 26.2
30-59 20.5 20.9 19.2 26.0 23.1 23.0
≤ 29 7.9 7.7 6.5 11.8 9.1 7.0
Unknown 15.0 13.9 10.6 13.7 12.7 12.2
Function status at transplant b b a
Severe impairment 32.4 30.4 31.5 33.6 38.9 31.0
Moderate impairment 24.7 25.3 23.6 22.9 25.3 25.7
Mild impairment 41.0 43.1 43.5 41.4 34.4 41.1
Unknown 1.9 1.3 1.4 2.2 1.5 2.1
Donor factors
Donor Risk Index score c a b b
0 to <1.5 33.0 34.3 34.5 37.6 34.5 36.8
1.5 to <2.0 34.3 36.4 35.0 35.4 36.8 34.8
2.0 to <2.5 19.7 19.0 18.7 18.1 18.3 17.1
≥ 2.5 8.5 6.9 7.7 6.5 6.6 7.1
Living donor 4.5 3.5 4.1 2.5 3.8 4.2
Transplant year a a b a a
2006-2009 9.3 12.6 16.4 10.9 12.0 17.1
2010-2012 44.0 45.8 48.1 41.3 53.6 53.3
2013-2014 46.7 41.6 35.5 47.8 34.4 29.6
P values for difference in distribution of case factors according to ISx regimen: aP < 0.0001; b 0.02 ≤ P < 0.05; c0.0001≤ P < 0.01.
AZA, azathioprine; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CsA, cyclosporine; eGFR, estimated glomerular filtration rate; MPA, mycophenolic acid; MELD, Model for End-Stage Liver
Disease; NASH, nonalcoholic steatohepatitis; Pred, prednisone; Tac, tacrolimus; mTORi, mammalian target of rapamycin inhibitor.
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Regimen Change Analysis
We examined the frequencies of liver transplant recipients
who remained on the same regimen after the 0- to 6-month
posttransplant period and those who switched to new regi-
mens in the 7- to 12-month period. To examine the correlates
of change in ISx, we performed multivariate logistic regression
modeling adjusted for recipient, donor, and transplant risk fac-
tors with “change in ISx regimen” as the dependent variable.
RESULTS
Between 2006 and 2014, 24 238 liver transplants were
performed in the US; 51 011 linked pharmacy fill records
were available. In the first 6months after transplant, a plural-
ity (42.9%) of transplant recipients received triple therapy;
18.1% received MPA/AZA-sparing (Tac alone, Tac+Pred),
15.4 steroid-sparing, 10.1% mTORi-based, and 8.8% CsA-
based. Most patients in the mTORi-based group also re-
ceived CNI (Tac, 72.5%; CsA, 12.4%). Induction therapy
at liver transplant varied with maintenance ISx regimen
(Table 1). Patients receiving triple ISx therapy were unlikely
to receive induction (81.7% did not), and those who did
most frequently received IL-2 receptor blocking antibodies
(IL2rAb, 14.6%). Conversely, induction was used in 40.1%
of patients on steroid-free regimens (TMG, 19.6%; IL2rAb,
17.5%) and in 32.7% of patients managed with MPA
avoidance (TMG, 14.6%; IL2rAb, 12.7%).
By 7 to 12 months after transplant, the pattern of ISx
shifted (Table 2; Figure S1, SDC, http://links.lww.com/
TXD/A103). Only 14.4% of patients remained on triple
therapy. Mycophenolic acid sparing regimens were the most
common (33.7%), followed by steroid-sparing (26.9%).
mTORi-based ISx was used in 12.1% and CsA-based in
9.2%. Only 27.0% of patients on triple therapy in the first
6 months remained, so at 6 to 12 months, 34.0% were
changed to steroid-sparing and 31.0% to MPA/AZA-sparing
regimens. In contrast, most patients on MPA/AZA-sparing
(82.0%), mTORi-based (79.3%), and CsA-based (80.6%)
ISx remained on their initial regimen.
Patient Characteristics and ISx Regimen Use
Some patient characteristics were associated with mainte-
nance ISx regimens at 0 to 6 months posttransplant (Table 3).
Younger patients (ages, 19-30 years) were less likely than
patients aged 31 to 45 years to receive steroid sparing versus
triple therapy (aOR 0.50 0.670.90). Older patients (age >45 years)
were more likely to receive MPA/AZA-sparing, mTORi-based,
or CsA-based regimens than to receive triple therapy
(P<0.05 for all). Black patients were less likely to receive
CsA-based regimens (aOR 0.590.720.89) and Hispanics were less
likely to receive mTORi-based regimens (aOR 0.620.740.88)
versus triple therapy. Recipients with low body mass index
(BMI) were more frequently given steroid-sparing and MPA/
AZA-sparing regimens. Compared with recipients with
alcoholic liver failure, those with HCC were 81% more
likely to receive mTORi-based regimens (aOR 1.48 1.812.21)
than triple therapy. Diabetic patients were more commonly
given MPA/AZA-sparing regimens than triple therapy
(aOR 1.112.445.39). The lower the estimated GFR (eGFR),
the higher the odds of receiving mTORi-based ISx (eGFR,
60-89: aOR 1.091.271.47; eGFR 30-59: aOR 1.381.601.86;
eGFR 0-29 ml/min/1.73 m2: aOR 1.732.112.58). Over time, use
of triple therapy was more likely compared with the other
ISx regimens, shown by aOR <1 for all nontriple therapy
regimens in 2010 to 2012 versus 2006 to 2009.
Associations of many case factors with ISx in months 7 to
12were similar to those in the first 6months (Table S1, http://
links.lww.com/TXD/A106). However, at 7 to 12 months, re-
cipients with BMI >30 kg/m2were significantlymore likely to
receive a steroid-sparing regimen (aOR 1.101.161.33). Recipi-
ents with ARwithin the first 6 months were more likely to re-
ceive triple therapy in the later period. In addition, recipients
with incident malignancy in first 6 months were 6 timesmore
likely (aOR 3.266.0711.27) to receive an mTORi-based regi-
men than to receive triple therapy. Among patients with se-
verely impaired functional status, CsA-based regimens were
more likely to be used (1.251.96 3.09).
Donor Characteristics and ISx Regimen Choice
Recipients of high Donor Risk Index score (≥2.5)
(aOR 0.630.79 0.99) or living donor (aOR 0.460.630.88) allo-
grafts were less likely to receive mTORi-based regimens
than to receive triple therapy (Table 3). Recipients who
had undergone previous transplant were more commonly
given MPA/AZA-sparing (aOR 1.211.411.64), CsA-based
(aOR 1.261.501.79), or other ISx maintenance (aOR 1.14
1.421.77) versus triple therapy.
Center Variation in ISx Use
Choice of ISx regimens differed substantially across centers
in the first 6 months after transplant (Figure 1). Regimen use
by center varied from 0% to 94.4% for triple therapy, 0%
TABLE 2.
ISx in months 7 to 12 compared with initial regimen months 0 to 6 posttransplant
Regimen months 7-12
% of Patients on indicated regimen in months 7-12
Tac + MPA/AZA + Pred Tac+MPA/AZA Tac alone, Tac+ Pred mTORi-based CsA-based Other
14.4 26.9 33.7 12.1 9.2 3.7
Regimen months 0-6 Patients on indicated regimen in months 6-12 who received reach regimen in months 7-12
Tac+MPA/AZA + Pred, % 27.0 34.0 31.0 3.4 1.5 3.2
Tac+MPA/AZA, % 5.2 56.9 29.3 3.7 1.5 3.5
Tac alone, Tac+Pred, % 4.5 6.9 82.0 3.7 1.8 1.1
mTORi-based, % 2.4 4.6 7.6 79.3 4.3 1.7
CsA-based, % 3.4 3.2 4.2 5.6 80.6 3.0
Other, % 10.6 25.7 15.4% 7.5% 5.6 35.1
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TABLE 3.
Associations of recipient, donor, and transplant case characteristics with liver transplant maintenance ISx regimen use
in months 0 to 6 posttransplant compared with triple therapy (reference regimen)
Tac + MPA/AZA Tac alone, Tac + Pred mTORi-based CsA-based Other
Induction regimen
No induction 0.74 (0.63-0.86)a 1.00 (0.86-1.16) 0.67 (0.57-0.78)a 0.97 (0.83-1.14) 0.86 (0.69-1.07)
Thymoglobulin 1.30 (1.01-1.67)b 1.58 (1.23,2.04)a 1.08 (0.81-1.44) 1.05 (0.78-1.42) 1.00 (0.68-1.48)
IL-2 receptor antibody Reference Reference Reference Reference Reference
Alemtuzumab 0.69 (0.28-1.69) 1.47 (0.69-3.14) 0.93 (0.38-2.29) 0.75 (0.29-1.95) 0.73 (0.21-2.50)
Other induction 0.97 (0.62-1.53) 1.28 (0.82-2.01) 1.10 (0.63-1.94) 1.08 (0.63-1.88) 0.96 (0.45-2.06)
Recipient characteristics
Age, y
18-30 0.67 (0.50-0.90)b 0.93 (0.73-1.18) 0.71 (0.49-1.01) 0.98 (0.70-1.36) 0.92 (0.64-1.32)
31-45 Reference Reference Reference Reference Reference
46-60 1.08 (0.92-1.27) 1.22 (1.05-1.41)b 1.41 (1.16-1.71)a 1.35 (1.12-1.63)c 1.07 (0.86-1.35)
>60 0.99 (0.83-1.19) 1.27 (1.08-1.49)b 1.64 (1.34-2.02)a 1.65 (1.34-2.02)a 1.04 (0.80-1.33)
Male 1.01 (0.92-1.12) 1.04 (0.95-1.14) 1.01 (0.90-1.12) 0.98 (0.88-1.09) 1.00 (0.86-1.15)
Race
White Reference Reference Reference Reference Reference
Black 0.93 (0.78-1.10) 0.93 (0.79-1.09) 0.87 (0.72-1.05) 0.72 (0.59-0.89)c 1.08 (0.86-1.36)
Hispanic 0.93 (0.79-1.09) 0.97 (0.83-1.12) 0.74 (0.62-0.88)c 1.04 (0.88-1.23) 1.05 (0.84-1.31)
Other 0.95 (0.76-1.20) 0.97 (0.78-1.20) 0.76 (0.59-0.98)b 0.74 (0.57-0.97)b 0.83 (0.59-1.17)
BMI, kg/m2
<18.5 1.53 (1.08-2.15)b 1.37 (1.00-1.89) 1.16 (0.75-1.77) 1.36 (0.93-2.00) 1.42 (0.89-2.28)
18.5-24.9 Reference Reference Reference Reference Reference
25-30 1.09 (0.97-1.24) 1.12 (1.00-1.25)b 1.03 (0.90-1.17) 1.05 (0.92-1.20) 1.18 (0.99-1.40)
>30 1.10 (0.97-1.24) 1.07 (0.95-1.20) 0.92 (0.80-1.05) 0.95 (0.83-1.09) 1.15 (0.96-1.38)
Unknown 1.83 (1.24-2.70)c 1.04 (0.72-1.49) 1.07 (0.69-1.64) 1.02 (0.61-1.71) 0.98 (0.57-1.68)
Cause of liver failure
Hepatocellular carcinoma 1.38 (1.15-1.67)c 1.23 (1.03-1.45)b 1.81 (1.48-2.21)a 0.96 (0.78-1.17) 1.52 (1.15-2.01)b
Hepatitis C 1.53 (1.30-1.81)a 1.22 (1.05-1.42)b 1.19 (0.99-1.43) 1.50 (1.26-1.78)a 1.59 (1.24-2.05)a
Hepatitis B 1.00 (0.68-1.47) 1.11 (0.78-1.58) 1.26 (0.84-1.91) 1.15 (0.76-1.72) 1.17 (0.66-2.08)
Metabolic 0.87 (0.61-1.24) 1.07 (0.79-1.45) 1.11 (0.77-1.60) 0.87 (0.60-1.26) 1.27 (0.77-2.07)
Alcoholic Reference Reference Reference Reference Reference
NASH 1.00 (0.80-1.24) 0.81 (0.66-1.00) 1.09 (0.87-1.38) 0.91 (0.72-1.16) 0.94 (0.66-1.33)
Other 0.64 (0.54-0.76)a 0.79 (0.68-0.92)b 0.79 (0.65-0.95)b 0.64 (0.53-0.77)a 1.16 (0.90-1.49)
Comorbidities
Diabetes 1.46 (0.57-3.76) 2.44 (1.11-5.39)b 1.66 (0.59-4.65) 1.01 (0.34-2.98) 1.29 (0.39-4.25)
Coronary artery disease/angina 1.25 (0.90-1.74) 1.01 (0.74-1.40) 0.94 (0.65-1.36) 1.18 (0.82-1.69) 1.01 (0.62-1.65)
COPD 1.32 (0.95-1.85) 0.82 (0.58-1.17) 0.82 (0.55-1.23) 1.21 (0.84-1.74) 1.11 (0.66-1.88)
Hypertension 0.99 (0.88-1.12) 0.90 (0.80-1.01) 1.05 (0.93-1.20) 0.98 (0.86-1.12) 1.10 (0.93-1.31)
Cerebral vascular disease 0.70 (0.38-1.31) 0.64 (0.35-1.18) 1.07 (0.59-1.93) 0.72 (0.37-1.43) 0.70 (0.28-1.72)
Peripheral vascular disease 1.33 (0.84-2.10) 0.60 (0.35-1.01) 0.75 (0.42-1.33) 0.81 (0.46-1.43) 0.62 (0.28-1.39)
Malignancy history 0.99 (0.87-1.12) 1.15 (1.02-1.29) 1.29 (1.13-1.47)a 1.02 (0.88-1.17) 0.84 (0.70-1.02)
Laboratory MELD score
10-14 0.99 (0.87-1.13) 1.05 (0.93-1.19) 0.99 (0.86-1.14) 0.88 (0.76-1.01) 1.17 (0.97-1.42)
15-19 Reference Reference Reference Reference Reference
20-24 0.99 (0.84-1.17) 1.02 (0.87-1.18) 1.10 (0.92-1.32) 1.00 (0.84-1.19) 1.15 (0.91-1.45)
25-29 0.95 (0.77-1.16) 1.05 (0.88-1.26) 1.05 (0.85-1.31) 1.09 (0.89-1.33) 1.12 (0.85-1.48)
30-34 0.88 (0.69-1.10) 0.95 (0.76-1.17) 1.04 (0.82-1.32) 1.04 (0.83-1.31) 1.02 (0.74-1.41)
35-39 0.91 (0.70-1.18) 1.09 (0.86-1.37) 0.94 (0.70-1.25) 0.80 (0.61-1.06) 0.85 (0.57-1.25)
≥40 0.93 (0.70-1.24) 1.10 (0.84-1.43) 1.05 (0.78-1.41) 0.97 (0.73-1.31) 1.13 (0.75-1.69)
Primary insurance
Private 1.03 (0.93-1.14) 0.87 (0.79-0.96)b 0.98 (0.88-1.09) 0.91 (0.82-1.02) 0.92 (0.80-1.06)
Public Reference Reference Reference Reference Reference
Self/other 0.86 (0.46-1.61) 1.53 (0.96-2.45) 1.09 (0.59-2.00) 1.55 (0.84-2.85) 1.68 (0.79-3.61)
Continued next page
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to 58.5% for steroid-sparing, 0% to 100% for MPA/AZA-
sparing, 0% to 50.0% for mTORi-based, and 0% to 45.6%
for CsA-based ISx. This variation across centers persisted at
7 to 12 months posttransplant (Figure S2, SDC, http://links.
lww.com/TXD/A104).
Hierarchical logistic regression models demonstrated that
between-center variation in use of specific ISx regimens was
significantly greater than expected based on differences in re-
cipient and donor characteristics (P<0.001) (Figure 2). In the
first 0 to 6 months posttransplant, 35.0% of centers used
steroid-sparing ISx more frequently than expected, 33.9%
used MPA/AZA-sparing more than expected; use of mTORi-
based and CsA-based ISx was higher than expected at
31.1% and 24.4% of centers, respectively (Table 4A). In
the 7- to 12-month period, centers were more uniform in
ISx patterns, shown as a reduction in the number of centers
with use above or below the reference probability and a
lower degree of heterogeneity (Table 4B; Figure S3, SDC,
http://links.lww.com/TXD/A105).
In the first 6 months posttransplant, unadjusted ICCs sug-
gest that 39% of the variation in steroid-sparing and MPA/
AZA-sparing ISx use was due to “center effect,” whereas
32% and 25% of the variation in mTORi-based and CsA-
based ISx, respectively, were driven by center preference
(Table 5A). Similar results were noted after adjustment of
ICC for recipient, donor, and transplant factors. Patient
characteristics explained less than 10% of the variation in use
of all regimens. Median odds ratio from case-factor adjusted
analysis varied from 2.8 to 4.0. Thus, a recipient with a given
set of characteristics was, on average, 4.0 times as likely to
receive a steroid- or antimetabolite-sparing regimen as triple
therapy, at specific centers. Between 6 and 12 months,
TABLE 3. (Continued)
Tac + MPA/AZA Tac alone, Tac + Pred mTORi-based CsA-based Other
Previous transplant 1.01 (0.84-1.21) 1.41 (1.21-1.64)a 0.93 (0.76-1.14) 1.50 (1.26-1.79)a 1.42 (1.14-1.77)c
eGFR at discharge, ml/min per 1.73 m2
≥90 Reference Reference Reference Reference Reference
60-89 0.95 (0.83-1.08) 0.92 (0.82-1.03) 1.27 (1.09-1.47)c 1.09 (0.94-1.26) 1.21 (1.01-1.45)b
30-59 0.97 (0.84-1.12) 0.84 (0.74-0.95)b 1.60 (1.38-1.86)a 1.09 (0.94-1.27) 1.21 (0.99-1.48)
≤29 1.10 (0.90-1.34) 0.71 (0.59-0.85)a 2.11 (1.73-2.58)a 1.03 (0.83-1.27) 0.95 (0.71-1.28)
Unknown 0.70 (0.56-0.87)b 0.78 (0.65-0.93)b 1.09 (0.87-1.36) 0.97 (0.77-1.23) 0.83 (0.62-1.12)
Function status at transplant
Severe impairment 1.09 (0.94-1.25) 1.12 (0.98-1.27) 1.09 (0.94-1.26)a 1.45 (1.25-1.68)a 1.11 (0.92-1.35)
Moderate impairment 1.06 (0.93-1.21) 0.97 (0.86-1.09) 1.03 (0.90-1.19) 1.18 (1.02-1.37)b 1.20 (1.00-1.44)b
Mild impairment Reference Reference Reference Reference Reference
Unknown 0.37 (0.24-0.57)a 0.79 (0.53-1.17) 0.57 (0.37-0.86)b 0.79 (0.49-1.28) 0.71 (0.40-1.28)
Donor factors
Donor Risk Index score
0 to <1.5 Reference Reference Reference Reference Reference
1.5 to <2.0 0.99 (0.88-1.11) 0.98 (0.88-1.09) 0.90 (0.79-1.01) 1.06 (0.93-1.20) 0.93 (0.79-1.09)
2.0 to <2.5 0.99 (0.86-1.15) 1.04 (0.92-1.19) 0.88 (0.75-1.02) 0.97 (0.83-1.14) 0.85 (0.70-1.05)
≥2.5 0.86 (0.70-1.05) 0.99 (0.82-1.18) 0.79 (0.63-0.99)b 0.83 (0.66-1.04) 0.90 (0.67-1.19)
Living donor 0.87 (0.65-1.16) 1.20 (0.95-1.53) 0.63 (0.46-0.88)b 0.89 (0.66-1.19) 1.07 (0.74-1.55)
Transplant year
2006-2009 Reference Reference Reference Reference Reference
2010-2012 0.60 (0.51-0.71)a 0.61 (0.53-0.70)a 0.71 (0.59-0.85)a 0.95 (0.80-1.14) 0.64 (0.52-0.79)a
2013-2014 0.43 (0.36-0.51)a 0.35 (0.30-0.40)a 0.67 (0.56-0.81)a 0.52 (0.43-0.63)a 0.26 (0.21-0.33)a
P values: a P < 0.0001; b 0.02 ≤ P < 0.05; c 0.0001 ≤ P < 0.01;
FIGURE 1. Proportion of patients receiving each maintenance ISx
option in months 0 to 6 after liver transplant across US centers
(2006-2014). Each horizontal bar represents an individual center
within US regions ordered by the proportion of patients receiving
each regimen.
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unadjusted and adjusted ICCs varied less due to “center
effect” across all ISx (Table 5B).
DISCUSSION
This study provides the first rigorous assessment of varia-
tion in long-term ISx regimen selection in liver transplant re-
cipients in a national cohort with a sample size large enough
to distinguish the effects of center practice and clinical case
factors. Our results suggest that liver transplant ISx is far
from uniform nationally, with selection of some regimens
varying from 0% to 100% of recipients across centers. The
degree of variation was higher in the first 6 months than in
months 7 to 12 after transplant, when minimized regimens
were favored. Multivariate analysis confirmed that center
protocol was a stronger determinant of ISx selection than pa-
tient or donor characteristics.
Overall, we observed a reduction in the intensity of ISx ex-
posure over time after liver transplant. Tac-based triple ISx
was the most commonly used maintenance regimen in the
first 6 months; however, only 23% of patients remained on
this regimen by months 7 to 12. In contrast, patients started
on reduced ISx regimens were more likely to remain on them.
Only 4.5% patients who initially received MPA/AZA-sparing
regimens and 5.2% who initially received steroid-sparing
regimens were converted to triple therapy during months
7 to 12 after transplant. This pattern may suggest that triple
therapy is not needed after liver transplant in many cases,
FIGURE 2. Empirical Bayes estimates for likelihood of use of eachmaintenance ISx regimen comparedwith triple therapy in months 0 to 6 after liver
transplant. The red bar demonstrates the national average rate of use of each regimen (within pairwise regimen comparisons). Each red dot represents
adjusted use at one center, and the blue bars reflect 95%CIs for use at the center determined by EBEs, adjusting for case factors of transplants at the
center; exclusion of the national average by a 95% CI reflects adjusted center use significantly above or below the national average.
TABLE 4.
Center-level EBEs adjusted for case-level characteristicsa
(A) Months 0-6
ISx regimen (reference:
Tac+MPA/AZA+Pred)
No. centers in
pairwise comparison
No. centers significantly
above reference probability
No. centers significantly
below reference probability
Tac+MPA/AZA 120 42 (35.0%) 38 (31.7%)
Tac alone, TAC+Pred 124 42 (33.9%) 38 (30.6%)
mTORi-based 122 38 (31.1%) 28 (23.0%)
CsA-based 123 30 (24.4%) 27 (22.0%)
Other 121 35 (28.9%) 20 (16.5%)
(B) Months 7-12
ISx regimen (reference:
Tac+MPA/AZA+Pred)
No. of centers in
pairwise comparison
No. of centers significantly
above reference probability
No. of centers significantly
below reference probability
Tac+MPA/AZA 120 27 (22.5%) 22 (18.3%)
Tac alone, TAC+Pred 123 27 (22.0%) 22 (17.9%)
mTORi-based 120 35 (29.2%) 25 (20.8%)
CsA-based 119 32 (26.9%) 19 (16.0%)
Other 118 22 (18.6%) 14 (11.9%)
a Constructed from pairwise comparisons of regimen of interest versus reference regimen of Tac + MPA/Aza + Pred.
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because AR rates are low and more than 90% of AR events
are steroid-responsive.1
The more frequent use of induction ISx in recipients man-
aged with regimens other than triple therapy may also have
contributed to the low conversion rate. In a nonrandomized
single-center trial, a steroid-free regimen and weaning to
single-agent Tac or SRL at 3 months after thymoglobulin induc-
tion yielded 1- and 5-year patient and graft survival comparable
to national averages in registry data.15 In a meta-analysis of
liver transplant recipients, AR was significantly less frequent
when any form of T cell–specific antibody induction was used
compared with no induction (relative risk, 0.85; P<0.05).16
The meta-analysis did not mirror typical practice patterns in
the US, however, as included studies were limited to 19 trials
with corticosteroids administered in all and MPA/AZA in
15 of the 19 trials. Thus, further study is needed to compare
the benefits and risks of early triple ISx, lower intensity ISx with
induction, and lower intensity ISx without induction.2,7,16
The national data demonstrate some expected associations
between ISx choice and recipient characteristics.Older recipients,
thosewithHCCor hepatitis C as cause of liver failure, and those
with renal insufficiency at discharge were less likely to be man-
aged with Tac-based triple therapy. At 7 to 12 months, use
of triple ISx was more likely in retransplant recipients and
in recipients with AR in the first 6 months. In contrast, recip-
ients with newly diagnosed malignancy were nearly 6 times
more likely to receive mTORi-based ISx.
The role of mTORi in the management of liver transplant
recipients with chronic renal insufficiency remains controver-
sial. In a randomized trial of standard dose, Tac versus
mTORi/reduced Tac, eGFR was 8 mL/min per 1.73 m2
higher in the reduced Tac group. Although there was no dif-
ference in the composite endpoint of death, graft loss, and
biopsy-proven rejection at 3 years (P = 0.33), there was a nu-
merically increased risk of AR in the reduced-Tac group
(9.2% vs 4.8%, P = 0.07), leading to study termination.7 A
meta-analysis reviewing mTORi and CNI-based ISx found
that patients converted to mTORi from CNIs had signifi-
cantly better renal function at 1 year after randomization.
Stratifying for conversion within 6 months versus later after
transplant suggested a trend toward more favorable eGFR
with early conversion. In our national data study, 20%of pa-
tients were converted from mTORi-based regimens to CNI-
based regimens, though only 2% were converted to triple
therapy. Further analysis is needed to define the outcomes
of mTORi-based ISx outside the clinical trial setting, and
to identify subgroups likely versus unlikely to benefit from
the regimen.
Among patients with HCC, we confirmed increased use of
mTORi-based ISx, which resonates with prior single-center
and meta-analytic data suggesting lower HCC recurrence
risk in patients treated with mTORis compared with
CNIs.17,18 The benefit of mTORi-based ISx remains ques-
tionable, however, given the results of a large randomized
trial. In the SiLVER study of 525 liver transplant recipients
withHCC, therewas no difference in recurrence-free survival
and patient survival with mTORi versus CNI at 5 years.19
However, there was significant benefit in recurrence-free
and overall survival over the first 3 years after transplant in
patients within Milan criteria who were given mTORi.
Furthermore, there was substantial heterogeneity in other
components of the ISx regimen across centers (eg, use of
induction, steroids, and CNIs), which may have affected
the trial findings.
Associations of metabolic risk factors with ISx selection
also warrant consideration. Among patients who underwent
transplant due to nonalcoholic steatohepatitis (NASH), triple
therapy may worsen diabetic control and contribute to end-
organ disease.20-24 Development of diabetes after transplant
was 29% higher in NASH recipients in one study, and may
be worsened by Tac and corticosteroids.25 In our study, dia-
betic patients were initially commonly treated with MPA/
AZA-sparing regimens (34.4%); 21.9% were given mono-
therapy with Tac. We found no association between ISx
TABLE 5.
Heterogeneity across unadjusted and both adjusted modelsa
(A) Months 0-6
ISx regimen (reference:
Tac+MPA/AZA+Pred)
Proportion of variance in hierarchical
model explained by center
characteristics (unadjusted)
MOR
(unadjusted)
Proportion of variance in hierarchical
model explained by center,
adjusted for case factors
MOR
(adjusted)
Proportion of variance in
model explained by
case factors
Tac+MPA/AZA 0.39 4.00 0.39 4.02 0.09
Tac alone, TAC+Pred 0.39 3.96 0.39 3.95 0.08
mTORi-based 0.32 3.25 0.32 3.28 0.06
CsA-based 0.25 2.75 0.25 2.74 0.06
Other 0.26 2.78 0.27 2.85 0.04
(B) Months 7-12
ISx regimen (reference:
Tac+MPA/AZA+Pred)
Proportion of variance in hierarchical
model explained by center
characteristics (unadjusted)
MOR
(unadjusted)
Proportion of variance in hierarchical
model explained by center,
adjusted for case factors
MOR
(adjusted)
Proportion of variance in
model explained by
case factors
Tac+MPA/AZA 0.19 2.31 0.23 2.56 0.06
Tac alone, TAC+Pred 0.24 2.61 0.26 2.76 0.07
mTORi-based 0.27 2.87 0.28 2.98 0.10
CsA-based 0.19 2.28 0.21 2.42 0.09
Other 0.14 2.01 0.16 2.10 0.04
a Proportion of variance in hierarchical model is equal to the ICC.
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choice and increased BMI in early regimen choice. However,
at 7 to 12 months, recipients with high BMI were significantly
more likely to receive a steroid-sparing regimen.We also noted
that recipients with severely impaired functional status and
lowBMIweremore likely to receive CsA-based regimens. This
association may reflect neurotoxicity associated chronic mal-
nutrition, which may worsen under Tac-based regimens,
resulting in early change to a CsA-based ISx.26
The limitations of the current study include its retrospec-
tive, nonrandomized design, although this offers benefits
with regard to sample size and national representation across
US transplant centers. We lacked precise information on ISx
exposure as we lacked data on ISx levels.We studied ISx over
the first year posttransplant, and ISx management may
change after the first posttransplant anniversary. The large
sample size and longitudinal follow-up allowed assessment
of changes in clinical characteristics over time (eg, development
of AR andmalignancy). However, other clinical conditions that
affect the choice of ISx are not identified in OPTN data or may
occur after the time of transplant, and therefore are not included
in this analysis. For example, recipients with a history of severe
CNI neurotoxicity, CNI-induced thrombotic microangiopathy,
or nephrotoxicity may be more likely to receive mTORi-based
therapy. Recipients receiving ISx through trials rather than
pharmacy fills cannot be identified through our study data,
although some recipients in the “other” category were likely
managed under study protocols. Finally, the years of data
collection in our study ended in 2014, and ongoing research
is needed to evaluate use of and trends in recently approved
agents, such as everolimus.27
In conclusion, we found that selection of ISx regimen after
liver transplant varies widely across US transplant centers
and largely reflects center choice rather than patient or donor
characteristics, similar to kidney transplant data we previ-
ously published.13,28 Whether tailoring ISx therapy to case
factors or using standardized protocols for all patients affects
posttransplant mortality remains to be defined. The current
observation of center-based practice variation frames a natu-
ral experiment for future studies to assess the effects of ISx
personalization on patient outcomes and costs with sufficient
power to identify low-probability events.
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